KLK3 and prostate carcinoma: Primary data from the phase 3 SPOTLIGHT study (NCT04186845) show high detection rates (DRs) and standard-of-truth (SoT)–verified DRs (VDRs) with 18F-flotufolastat for the accurate localization of recurrent prostate cancer across wide-ranging PSA values, alongside a favorable safety profile (14–16).